Literature DB >> 33425900

Molecular Pathways Modulated by Mesenchymal Stromal Cells and Their Extracellular Vesicles in Experimental Models of Liver Fibrosis.

Giulia Chiabotto1,2, Chiara Pasquino1,2, Giovanni Camussi1,2, Stefania Bruno1,2.   

Abstract

End-stage liver fibrosis is common to all chronic liver diseases. Since liver transplantation has several limitations, including lack of donors, immunological rejection, and high medical costs, therapeutic alternatives are needed. The administration of mesenchymal stromal cells (MSCs) has been proven effective in tissue regeneration after damage. However, the risk of uncontrolled side effects, such as cellular rejection and tumorigenesis, should be taken into consideration. A safer alternative to MSC transplantation is represented by the MSC secretome, which retains the same beneficial effect of the cell of origin, without showing any considerable side effect. The paracrine effect of MSCs is mainly carried out by secreted particles in the nanometer range, known as extracellular vesicles (EVs) that play a fundamental role in intercellular communication. In this review, we discuss the current literature on MSCs and MSC-EVs, focusing on their potential therapeutic action in liver fibrosis and on their molecular content (proteins and RNA), which contributes in reverting fibrosis and prompting tissue regeneration.
Copyright © 2020 Chiabotto, Pasquino, Camussi and Bruno.

Entities:  

Keywords:  collagen; exosomes; fibrosis; hepatic stellate cell; inflammation; mesenchymal stem cell; microvesicles; α-SMA

Year:  2020        PMID: 33425900      PMCID: PMC7794013          DOI: 10.3389/fcell.2020.594794

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  6 in total

1.  Human amniotic mesenchymal stem cells-derived IGFBP-3, DKK-3, and DKK-1 attenuate liver fibrosis through inhibiting hepatic stellate cell activation by blocking Wnt/β-catenin signaling pathway in mice.

Authors:  Quan-Wen Liu; Yan-Min Ying; Jia-Xin Zhou; Wen-Jie Zhang; Zhao-Xiao Liu; Bing-Bing Jia; Hao-Cheng Gu; Chu-Yu Zhao; Xiao-Hui Guan; Ke-Yu Deng; Hong-Bo Xin
Journal:  Stem Cell Res Ther       Date:  2022-06-03       Impact factor: 8.079

2.  Human liver stem cell-derived extracellular vesicles reduce injury in a model of normothermic machine perfusion of rat livers previously exposed to a prolonged warm ischemia.

Authors:  Nicola De Stefano; Victor Navarro-Tableros; Dorotea Roggio; Alberto Calleri; Federica Rigo; Ezio David; Alessandro Gambella; Daniela Bassino; Antonio Amoroso; Damiano Patrono; Giovanni Camussi; Renato Romagnoli
Journal:  Transpl Int       Date:  2021-09       Impact factor: 3.842

Review 3.  Extracellular vesicles in inflammation: Focus on the microRNA cargo of EVs in modulation of liver diseases.

Authors:  Mrigya Babuta; Gyongyi Szabo
Journal:  J Leukoc Biol       Date:  2021-11-10       Impact factor: 6.011

4.  From hair to liver: emerging application of hair follicle mesenchymal stem cell transplantation reverses liver cirrhosis by blocking the TGF-β/Smad signaling pathway to inhibit pathological HSC activation.

Authors:  Qi Liu; Chengqian Lv; Yanan Jiang; Kunpeng Luo; Yang Gao; Jingyang Liu; Xu Zhang; Jan Mohammad Omar; Shizhu Jin
Journal:  PeerJ       Date:  2022-02-15       Impact factor: 2.984

Review 5.  The Agonists of Peroxisome Proliferator-Activated Receptor-γ for Liver Fibrosis.

Authors:  Jingjing Li; Chuanyong Guo; Jianye Wu
Journal:  Drug Des Devel Ther       Date:  2021-06-18       Impact factor: 4.162

Review 6.  Regenerative Potential of Mesenchymal Stem Cells' (MSCs) Secretome for Liver Fibrosis Therapies.

Authors:  Simona-Rebeca Nazarie Ignat; Sami Gharbia; Anca Hermenean; Sorina Dinescu; Marieta Costache
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.